Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactococcus lactis MG1363-pMG36e-glucagon-like peptide-1
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactococcus lactis MG1363-pMG36e-glucagon-like peptide-1 is an engineered, next-generation probiotic strain designed to provide continuous delivery of glucagon-like peptide-1 (GLP-1). It is constructed by transforming the *Lactococcus lactis* MG1363 strain with the pMG36e-GLP-1 expression vector, which contains the GLP-1 (1-37) gene sequence. This microbial therapy aims to overcome the short half-life of native GLP-1 by utilizing the bacteria as a living factory for the peptide within the gut. Research indicates that this strain exerts neuroprotective effects in models of Parkinson's disease by modulating oxidative stress, inhibiting ferroptosis via the Keap1/Nrf2/GPX4 pathway, and redressing gut dysbiosis. It has also been investigated for potential applications in Alzheimer's disease and obesity induced by a high-fat diet.
- Other names
- Lactococcus lactis MG1363-pMG36e-GLP-1pMG36e-GLP-1-transformed L. lactis MG1363pMG-36e-GLP-1-transformed L. lactis MG1363pMG 36e-GLP-1-transformed L. lactis MG1363
02
Targets
Beyond the preview
Go deeper on Lactococcus lactis MG1363-pMG36e-glucagon-like peptide-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactococcus lactis MG1363-pMG36e-glucagon-like peptide-1.